Clinical Development Equipment
-
Manufactured by Frontier Biotechnologies Inc.based in CHINA
FB2001 (generic name: Bofutrelvir) is a SARS-CoV-2 3CL protease inhibitor under clinical development for hospitalized patients as well as for post-exposure prophylaxis of Covid-19. It is a peptidomimetic compound targeting 3CL-protease based on three-dimensional crystal structure of the protease. Preclinical data has shown it has potent ...
-
Manufactured by AB2 Bio Ltd.based in SWITZERLAND
Macrophage Activation Syndrome. Macrophage Activation Sysdrome (MAS) is a very severe complication of rheumatic diseases. Mortality ranges between 10-30% for patients with MAS and there is no registered therapy. MAS occurs frequently in systemic Juvenile Idiopathic Arthritis (soJIA) and in Adult onset Still’s Disease (AOSD) patients. It is characterized by severe systemic inflammation with ...
-
Manufactured by AB2 Bio Ltd.based in SWITZERLAND
People with HLH usually develop symptoms within the first months or years of life. Symptoms may include fever, enlarged liver or spleen, cytopenia (decreased number of blood cells), and neurological abnormalities. All forms of HLH, including cases treated adequately, may have a high mortality rate. The long-term outlook (prognosis) of ...
-
by Vivozon Inc.based in SOUTH KOREA
A randomized, double-blind, placebo-controlled, single and repeated dose, escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VVZ-149 injection in healthy adult ...
-
by Vivozon Inc.based in SOUTH KOREA
Single-dose, escalation clinical trial to evaluate the safety and pharmacokinetics of VVZ-149 injection in healthy elderly ...
-
by Vivozon Inc.based in SOUTH KOREA
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic gastrectomy in early gastric cancer ...
-
by Vivozon Inc.based in SOUTH KOREA
A Randomized, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for post-operative pain following laparoscopic colorectal ...
-
by Vivozon Inc.based in SOUTH KOREA
Analgesic efficacy and safety of VVZ-149 injections for post-operative pain following laparoscopic colorectal surgery: a randomized, double-blind, parallel group, placebo-controlled, dose finding ...
-
by Vivozon Inc.based in SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
-
by Vivozon Inc.based in SOUTH KOREA
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic and robotic-laparoscopic ...
-
by Vivozon Inc.based in SOUTH KOREA
A randomized, double-blind, parallel group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after artificial hip replacement ...
-
Manufactured by Arch Oncology, Inc.based in USA
We are advancing our pipeline of antibodies for the treatment of patients with cancer. AO-176 is a highly differentiated anti-CD47 IgG2 antibody currently in clinical trials for solid tumors and multiple myeloma. AO-176 works by blocking the “don’t eat me” signal enabled by CD47’s interaction with SIRPa and ...
-
Manufactured by Ariana Pharmabased in FRANCE
Ariana® has consolidated multiple, publicly available administrative healthcare admissions databases into a locally searchable observational health data resource of patient hospitalization, outpatient and other episodes, comprising in excess of 6B records. ...
-
Manufactured by Alzinova ABbased in SWEDEN
ALZ-101 is a vaccine that stimulates the production of antibodies against the toxic Aβ oligomers. A first-in-human study in patients with early Alzheimer’s disease was initiated during third quarter of ...
-
Manufactured by AlloVirbased in USA
ALVR109 is being developed as an allogeneic, off-the-shelf VST therapy designed to arrest the progression of COVID-19 by eradicating SARS-CoV-2 virus-infected cells. ...
-
Manufactured by EsoCap AGbased in SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
-
Manufactured by HepaRegeniX GmbHbased in GERMANY
HepaRegeniX has started to progress the clinical development of its proprietary candidates e.g. ...
-
Manufactured by Anaveon AGbased in SWITZERLAND
The culmination of our research is ANV419, which is in clinical development. It is a rationally engineered fusion protein that is a stable, antibody-like molecule. ...
-
Manufactured by Apyx Medical Corporationbased in USA
Renuvion cosmetic technology is the result of extensive scientific research and clinical development. Because of its proprietary balance of helium and RF energy, Renuvion has been described as ideal for medical procedures where precision and control are key to an effective ...
-
Manufactured by Idience Co., Ltdbased in SOUTH KOREA
ID11916 is unique as it is the first drug that combines AR antagonism and phosphodiesterase type 5 (PDE5) inhibition into one small molecule targeting androgen receptor over-expressed solid tumors. ID11916 has an improved anti-cancer effect that overcomes the limitations of pre-existing anti-AR. It is currently under pre-clinical development. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you